Those Who Invested in Krystal Biotech (NASDAQ:KRYS) Five Years Ago Are up 329%
Those Who Invested in Krystal Biotech (NASDAQ:KRYS) Five Years Ago Are up 329%
Long term investing can be life changing when you buy and hold the truly great businesses. While the best companies are hard to find, but they can generate massive returns over long periods. Just think about the savvy investors who held Krystal Biotech, Inc. (NASDAQ:KRYS) shares for the last five years, while they gained 329%. And this is just one example of the epic gains achieved by some long term investors. In the last week shares have slid back 2.5%.
當你買入並持有真正優秀的業務時,長期投資可以改變人生。雖然最好的公司很難找到,但是在長期內它們可以帶來巨大的回報。想一想那些持有Krystal Biotech, Inc.(NASDAQ:KRYS)股票五年的聰明投資者,他們賺了329%。這只是長期投資者實現的一次巨大收益的例子之一。在過去的一週裏,股票已經下跌了2.5%。
Let's take a look at the underlying fundamentals over the longer term, and see if they've been consistent with shareholders returns.
讓我們長期看一下潛在的基本面,看看它們是否與股東回報一致。
While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.
雖然市場是一個強大的定價機制,但股價反映了投資者情緒,不僅僅是基本業績。一種有缺陷但合理的評估公司周圍情緒如何變化的方法是將每股收益(EPS)與股價進行比較。
During the last half decade, Krystal Biotech became profitable. Sometimes, the start of profitability is a major inflection point that can signal fast earnings growth to come, which in turn justifies very strong share price gains.
在過去的五年中,Krystal Biotech實現了盈利。有時候,盈利的開始是一個重大的轉折點,可以預示着未來快速的收益增長,這反過來又可以證明股價的大幅上漲是合理的。
The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).
該公司的每股收益(隨時間的推移)如下圖所示(單擊可查看確切數字)。
![earnings-per-share-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240619/0-ff621402d6685ed1d716fe8077ab7caf-0-a51af65a166f4b3fb79e1a054ba34faa.png/big)
We know that Krystal Biotech has improved its bottom line lately, but is it going to grow revenue? This free report showing analyst revenue forecasts should help you figure out if the EPS growth can be sustained.
我們知道Krystal Biotech最近已經改善了其底線,但其營業收入是否會增長呢?這份提供分析師營業收入預測的免費報告應該可以幫助您確定EPS增長是否可持續。
A Different Perspective
不同的觀點
It's good to see that Krystal Biotech has rewarded shareholders with a total shareholder return of 39% in the last twelve months. That gain is better than the annual TSR over five years, which is 34%. Therefore it seems like sentiment around the company has been positive lately. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Take risks, for example - Krystal Biotech has 2 warning signs (and 1 which is concerning) we think you should know about.
很高興看到Krystal Biotech在過去12個月中爲股東提供了39%的總股東回報。這個收益比5年期間的年度TSR(34%)要好。因此,目前公司周圍的情緒似乎是積極的。在最好的情況下,這可能暗示着一些真正的業務動力,這意味着現在可能是深入研究其股票的好時機。儘管考慮市場條件可能對股價產生的不同影響是非常值得的,但有其他更重要的因素。拿風險來說,Krystal Biotech有2個警告信號(並且1個令人擔憂),我們認爲您應該知道。
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.
如果您願意查看另一家公司(具有潛在的更好財務狀況),請不要錯過這個免費的公司列表,證明它們可以增長收益。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
請注意,本文所引述的市場回報反映了目前在美國交易所上市的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,也可以發送電子郵件至editorial-team@simplywallst.com